Interacting mechanisms in the pathogenesis of cardiac allograft vasculopathy.

Cardiac allograft vasculopathy is the major cause of late graft loss in heart transplant recipients. Histological studies of characteristic end-stage lesions reveal arterial changes consisting of a diffuse, confluent, and concentric intimal expansion containing graft-derived cells expressing smooth muscle markers, extracellular matrix, penetrating microvessels, and a host mononuclear cell infiltrate concentrated subjacent to an intact graft-derived luminal endothelial cell lining with little evidence of acute injury. This intimal expansion combined with inadequate compensatory outward remodeling produces severe generalized stenosis extending throughout the epicardial and intramyocardial arterial tree that causes ischemic graft failure. Cardiac allograft vasculopathy lesions affect ≥50% of transplant recipients and are both progressive and refractory to treatment, resulting in ≈5% graft loss per year through the first 10 years after transplant. Lesions typically stop at the suture line, implicating alloimmunity as the primary driver, but pathogenesis may be multifactorial. Here, we will discuss 6 potential contributors to lesion formation (1) conventional risk factors of atherosclerosis; (2) pre- or peritransplant injuries; (3) infection; (4) innate immunity; (5) T-cell-mediated immunity; and (6) B-cell-mediated immunity through production of donor-specific antibody. Finally, we will consider how these various mechanisms may interact with each other.

[1]  Stavros G Drakos,et al.  Coronary computed tomography angiography for the detection of cardiac allograft vasculopathy: a meta-analysis of prospective trials. , 2014, Journal of the American College of Cardiology.

[2]  K. Brayman,et al.  Natural IgM Anti-leucocyte Autoantibodies (IgM-ALA) Regulate Inflammation Induced by Innate and Adaptive Immune Mechanisms , 2014, Journal of Clinical Immunology.

[3]  E. Reed,et al.  Antibody-mediated graft injury: complement-dependent and complement-independent mechanisms , 2014, Current opinion in organ transplantation.

[4]  J. Pober,et al.  Alloantibody and Complement Promote T Cell–Mediated Cardiac Allograft Vasculopathy Through Noncanonical Nuclear Factor-&kgr;B Signaling in Endothelial Cells , 2013, Circulation.

[5]  Josef Stehlik,et al.  The Registry of the International Society for Heart and Lung Transplantation: Thirtieth Official Adult Heart Transplant Report--2013; focus theme: age. , 2013, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[6]  R. Lechler,et al.  Origin and biology of the allogeneic response. , 2013, Cold Spring Harbor perspectives in medicine.

[7]  A. Sharif,et al.  Delayed graft function after kidney transplantation: the clinical perspective. , 2013, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[8]  P. Libby,et al.  Immune effector mechanisms implicated in atherosclerosis: from mice to humans. , 2013, Immunity.

[9]  G. Weisz,et al.  Detection and imaging of cardiac allograft vasculopathy. , 2013, JACC. Cardiovascular imaging.

[10]  M. Rosenfeld Inflammation and atherosclerosis: direct versus indirect mechanisms. , 2013, Current opinion in pharmacology.

[11]  J. Wald,et al.  Correlation of circulating donor-specific anti-HLA antibodies and presence of C4d in endomyocardial biopsy with heart allograft outcomes: a single-center, retrospective study. , 2013, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[12]  Roberto A. Maldonado,et al.  Rapamycin-treated human endothelial cells preferentially activate allogeneic regulatory T cells. , 2013, The Journal of clinical investigation.

[13]  D. Duprez,et al.  Endothelial Dysfunction and Cardiac Allograft Vasculopathy , 2013, Journal of Cardiovascular Translational Research.

[14]  R. Shemin,et al.  Primary graft dysfunction does not lead to increased cardiac allograft vasculopathy in surviving patients. , 2013, The Journal of thoracic and cardiovascular surgery.

[15]  R. Colvin,et al.  Role of complement and NK cells in antibody mediated rejection. , 2012, Human immunology.

[16]  H. Ross,et al.  Factors associated with the development of cardiac allograft vasculopathy – a systematic review of observational studies , 2012, Clinical transplantation.

[17]  R. Colvin,et al.  A Novel Pathway of Chronic Allograft Rejection Mediated by NK Cells and Alloantibody , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[18]  P. Heeger,et al.  Novel roles of complement in T effector cell regulation. , 2012, Immunobiology.

[19]  W. Sessa,et al.  Reperfusion Injury Intensifies the Adaptive Human T Cell Alloresponse in a Human-Mouse Chimeric Artery Model , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[20]  J. Pober,et al.  Neutralizing IL-6 Reduces Human Arterial Allograft Rejection by Allowing Emergence of CD161+ CD4+ Regulatory T Cells , 2011, The Journal of Immunology.

[21]  A. Nègre-Salvayre,et al.  A Key Role for Matrix Metalloproteinases and Neutral Sphingomyelinase-2 in Transplant Vasculopathy Triggered by Anti-HLA Antibody , 2011, Circulation.

[22]  J. Pober,et al.  Transforming Growth Factor Beta Expression by Human Vascular Cells Inhibits Interferon Gamma Production and Arterial Media Injury by Alloreactive Memory T Cells , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[23]  A. Kirtane,et al.  Cardiac allograft vasculopathy , 2017 .

[24]  M. Huibers,et al.  Intimal fibrosis in human cardiac allograft vasculopathy. , 2011, Transplant immunology.

[25]  A. Mehrotra,et al.  Anticardiac Myosin Immunity and Chronic Allograft Vasculopathy in Heart Transplant Recipients , 2011, The Journal of Immunology.

[26]  G. Ewald,et al.  A Role for Antibodies to Human Leukocyte Antigens, Collagen-V, and K-&agr;1-Tubulin in Antibody-Mediated Rejection and Cardiac Allograft Vasculopathy , 2011, Transplantation.

[27]  M. Colvin-adams,et al.  Cardiac allograft vasculopathy: current knowledge and future direction , 2011, Clinical transplantation.

[28]  J. Madsen,et al.  Innate immunity and cardiac allograft rejection. , 2010, Kidney international. Supplement.

[29]  K. Wood,et al.  In vivo Prevention of Transplant Arteriosclerosis by ex vivo Expanded Human Regulatory T Cells , 2010, Nature Medicine.

[30]  M. Halushka,et al.  B Cells and Plasma Cells in Coronaries of Chronically Rejected Cardiac Transplants , 2010, Transplantation.

[31]  R. Negrin,et al.  Biology and clinical effects of natural killer cells in allogeneic transplantation , 2010, Current opinion in oncology.

[32]  A. Nègre-Salvayre,et al.  HLA Class I Antibodies Provoke Graft Arteriosclerosis in Human Arteries Transplanted into SCID/Beige Mice , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[33]  R. Mitchell,et al.  Graft vascular disease: immune response meets the vessel wall. , 2009, Annual review of pathology.

[34]  J. Pober,et al.  Interleukin (IL)-1 promotes allogeneic T cell intimal infiltration and IL-17 production in a model of human artery rejection , 2008, The Journal of experimental medicine.

[35]  C. Colangelo,et al.  Amelioration of Human Allograft Arterial Injury by Atorvastatin or Simvastatin Correlates With Reduction of Interferon-γ Production by Infiltrating T Cells , 2008, Transplantation.

[36]  X. Zhang,et al.  Macrophage activation by endogenous danger signals , 2008, The Journal of pathology.

[37]  B. Ryffel,et al.  Role of pattern-recognition receptors in cardiovascular health and disease. , 2007, Biochemical Society transactions.

[38]  J. Madsen,et al.  Macrophage Depletion Suppresses Cardiac Allograft Vasculopathy in Mice , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[39]  K. Tracey,et al.  IL-1α and IL-1β Are Endogenous Mediators Linking Cell Injury to the Adaptive Alloimmune Response1 , 2007, The Journal of Immunology.

[40]  J. Pober,et al.  Interferon-&ggr; Induces Human Vascular Smooth Muscle Cell Proliferation and Intimal Expansion by Phosphatidylinositol 3-Kinase–Dependent Mammalian Target of Rapamycin Raptor Complex 1 Activation , 2007, Circulation research.

[41]  H. Valantine,et al.  Cytomegalovirus-associated allograft rejection in heart transplant patients , 2007, Current opinion in infectious diseases.

[42]  J. Pober,et al.  Interferon-&ggr; Axis in Graft Arteriosclerosis , 2007 .

[43]  W. Baldwin,et al.  Antibody and complement in transplant vasculopathy. , 2007, Circulation research.

[44]  Rodney K. Chan,et al.  The Differing Roles of the Classical and Mannose-Binding Lectin Complement Pathways in the Events following Skeletal Muscle Ischemia-Reperfusion1 , 2006, The Journal of Immunology.

[45]  B. McManus,et al.  Allograft Vasculopathy Versus Atherosclerosis , 2006, Circulation research.

[46]  M. Mehra,et al.  Contemporary Concepts in Prevention and Treatment of Cardiac Allograft Vasculopathy , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[47]  J. Pober,et al.  Human Allograft Arterial Injury Is Ameliorated by Sirolimus and Cyclosporine and Correlates with Suppression of Interferon-&ggr; , 2006, Transplantation.

[48]  J. Saffitz,et al.  Extracardiac Progenitor Cells Repopulate Most Major Cell Types in the Transplanted Human Heart , 2005, Circulation.

[49]  R. Colvin,et al.  NK Cells Can Trigger Allograft Vasculopathy: The Role of Hybrid Resistance in Solid Organ Allografts1 , 2005, The Journal of Immunology.

[50]  C. Mavroudis,et al.  Neointimal inflammation and adventitial angiogenesis correlate with severity of cardiac allograft vasculopathy in pediatric recipients. , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[51]  M. Thomsen,et al.  Chronic vascular rejection: histologic comparison between two murine experimental models. , 2005, Transplantation proceedings.

[52]  B. Meiser,et al.  HLA-DR matching improves survival after heart transplantation: is it time to change allocation policies? , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[53]  W. Sessa,et al.  T cell-mediated vascular dysfunction of human allografts results from IFN-gamma dysregulation of NO synthase. , 2004, The Journal of clinical investigation.

[54]  William R. Burns,et al.  Interferon‐γ plays a nonredundant role in mediating T‐cell‐ dependent outward vascular remodeling of allogeneic human coronary arteries , 2004 .

[55]  L. Klein,et al.  Coronary Endothelial Dysfunction After Heart Transplantation Predicts Allograft Vasculopathy and Cardiac Death , 2002, Circulation.

[56]  J. Pober,et al.  Interferon-γ elicits arteriosclerosis in the absence of leukocytes , 2000, Nature.

[57]  J. Pober,et al.  Human allogeneic vascular rejection after arterial transplantation and peripheral lymphoid reconstitution in severe combined immunodeficient mice. , 1999, Transplantation.

[58]  B. McManus,et al.  Human transplant coronary artery disease: pathological evidence for Fas-mediated apoptotic cytotoxicity in allograft arteriopathy. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[59]  P. Libby,et al.  Human vascular smooth muscle cells poorly co-stimulate and actively inhibit allogeneic CD4+ T cell proliferation in vitro. , 1995, Journal of immunology.

[60]  P. Libby,et al.  Human coronary transplantation-associated arteriosclerosis. Evidence for a chronic immune reaction to activated graft endothelial cells. , 1991, The American journal of pathology.

[61]  J. Wald,et al.  Antibody-mediated rejection in heart transplant patients: long-term follow up of patients with high levels of donor-directed anti-DQ antibodies. , 2011, Clinical transplants.

[62]  M. Weiss,et al.  Mechanisms of chronic rejection in cardiothoracic transplantation. , 2008, Frontiers in bioscience : a journal and virtual library.

[63]  J. Cecka Kidney transplantation in the United States. , 2008, Clinical transplants.

[64]  J. Pober,et al.  Interferon-gamma axis in graft arteriosclerosis. , 2007, Circulation research.

[65]  K. Tracey,et al.  IL-1alpha and IL-1beta are endogenous mediators linking cell injury to the adaptive alloimmune response. , 2007, Journal of immunology.

[66]  W. Burns,et al.  Interferon-gamma plays a nonredundant role in mediating T cell-dependent outward vascular remodeling of allogeneic human coronary arteries. , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[67]  J. Pober,et al.  Interferon-gamma elicits arteriosclerosis in the absence of leukocytes. , 2000, Nature.

[68]  R. Ross,et al.  Mechanisms of atherosclerosis--a review. , 1990, Advances in nephrology from the Necker Hospital.